[HTML][HTML] Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis
…, B Jarosz, B Czartoryska-Arłukowicz… - Breast Cancer …, 2016 - Springer
… Bogumiła Czartoryska-Arłukowicz …
[HTML][HTML] Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain
…, T Mandat, W Och, B Czartoryska-Arłukowicz… - Breast cancer …, 2012 - Springer
Introduction We investigated the status of estrogen receptor alpha (ERα), progesterone
receptor (PR), and epidermal growth factor receptor 2 (HER2) in primary tumor and in the …
receptor (PR), and epidermal growth factor receptor 2 (HER2) in primary tumor and in the …
[HTML][HTML] Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients
…, B Czartoryska-Arłukowicz… - Journal of Neuro …, 2015 - Springer
The overexpression or amplification of the human epidermal growth factor receptor 2 gene (HER2/neu)
is associated with high risk of brain metastasis (BM). The identification of patients …
is associated with high risk of brain metastasis (BM). The identification of patients …
DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer
…, W Och, B Czartoryska-Arlukowicz… - JNCI: Journal of the …, 2014 - academic.oup.com
Background Breast cancer frequently metastasizes to the brain, colonizing a neuro-inflammatory
microenvironment. The molecular pathways facilitating this colonization remain poorly …
microenvironment. The molecular pathways facilitating this colonization remain poorly …
Risk factors for brain relapse in HER2-positive metastatic breast cancer patients
…, R Dziadziuszko, B Czartoryska-Arłukowicz… - Breast cancer research …, 2009 - Springer
Brain relapse is a common occurrence in HER2-positive breast cancer patients. However,
the factors determining the risk of brain metastasis in these patients remain to be established. …
the factors determining the risk of brain metastasis in these patients remain to be established. …
Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab …
…, A Paquet, Y Lie, B Czartoryska-Arłukowicz… - The …, 2012 - academic.oup.com
Background. Patients with human epidermal growth factor receptor (HER)-2 + breast cancer
are at particularly high risk for brain metastases; however, the biological basis is not fully …
are at particularly high risk for brain metastases; however, the biological basis is not fully …
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
…, A Kowalczyk, B Czartoryska-Arłukowicz… - Neuro …, 2015 - academic.oup.com
Background Patients with advanced breast cancer positive for human epidermal growth
factor receptor 2 (HER2) are at high risk for brain metastasis (BM). The prevalence and …
factor receptor 2 (HER2) are at high risk for brain metastasis (BM). The prevalence and …
Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the …
…, T Jankowski, B Czartoryska-Arłukowicz… - Clinical Cancer …, 2014 - AACR
Purpose: P95HER2 (p95) is a truncated form of the HER2, which lacks the trastuzumab-binding
site and contains a hyperactive kinase domain. Previously, an optimal clinical cutoff of …
site and contains a hyperactive kinase domain. Previously, an optimal clinical cutoff of …
Brain metastasis prediction by transcriptomic profiling in triple-negative breast cancer
…, A Musolino, B Czartoryska-Arłukowicz… - Clinical breast …, 2017 - Elsevier
Background Triple-negative breast cancer (TNBC) lacks expression of steroid hormone
receptors (estrogen receptor α and progesterone) and epidermal growth factor receptor type 2. …
receptors (estrogen receptor α and progesterone) and epidermal growth factor receptor type 2. …
[HTML][HTML] Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following …
R Duchnowska, J Sperinde, B Czartoryska-Arłukowicz… - Oncotarget, 2017 - ncbi.nlm.nih.gov
… Renata Duchnowska, 1 Jeff Sperinde, 2 Bogumiła Czartoryska-Arłukowicz, 3 Paulina Myśliwiec,
4 John Winslow, 2 Barbara Radecka, 5 Christos Petropoulos, 2 Regina Demlova, 6 Marlena …
4 John Winslow, 2 Barbara Radecka, 5 Christos Petropoulos, 2 Regina Demlova, 6 Marlena …